TrianglePembrolizumab (NCT05132504)
Pembrolizumab trial for Pancreatic Ductal Adenocarcinoma (NCT05132504). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with localized, resectable pancreatic adenocarcinoma and no previous chemotherapy or radiation for it. Borderline-resectable, unresectable, and metastatic disease are excluded.
The idea: pembrolizumab blocks PD-1 to release an immune brake. Patients receive six two-week FOLFIRINOX cycles with two pembrolizumab doses before surgery. Afterward, up to six cycles of fluorouracil-based chemotherapy accompany seven more pembrolizumab doses. Pembrolizumab is given every six weeks. Researchers assess pathological response and safety.
This phase 2 study plans 30 patients. Ernest Camp leads at Baylor College of Medicine; three Houston sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.